Evidence map›Paper›PMID 33043046›Full record

ReviewERJ open research2020

Respiratory dysfunction in Parkinson's disease: a narrative review.

Andrea D'Arrigo, Stefano Floro, Francesca Bartesaghi, Chiara Casellato, Giuseppe Francesco Sferrazza Papa, Stefano Centanni, Alberto Priori, Tommaso Bocci

Abstract readReview
In one paragraph

Review in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea D'Arrigo"Aldo Ravelli" Center, Dept of Health Sciences, University of Milan Medical School and San Paolo University Hospital, ASST Santi Paolo e Carlo Milano, Milan, Italy.
Stefano Floro"Aldo Ravelli" Center, Dept of Health Sciences, University of Milan Medical School and San Paolo University Hospital, ASST Santi Paolo e Carlo Milano, Milan, Italy.
Francesca Bartesaghi"Aldo Ravelli" Center, Dept of Health Sciences, University of Milan Medical School and San Paolo University Hospital, ASST Santi Paolo e Carlo Milano, Milan, Italy.
Chiara Casellato"Aldo Ravelli" Center, Dept of Health Sciences, University of Milan Medical School and San Paolo University Hospital, ASST Santi Paolo e Carlo Milano, Milan, Italy.
Giuseppe Francesco Sferrazza PapaRespiratory Unit, Dept of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Stefano CentanniRespiratory Unit, Dept of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Alberto Priori"Aldo Ravelli" Center, Dept of Health Sciences, University of Milan Medical School and San Paolo University Hospital, ASST Santi Paolo e Carlo Milano, Milan, Italy.
Tommaso Bocci"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Dept of Health Sciences, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0001-8874-1070

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of respiratory symptoms in Parkinson's disease (PD) has been known since the first description of the disease, even though the prevalence and incidence of these disturbances are not well defined. Several causes have been reported, comprising obstructive and restrictive pulmonary disease and changes in the central ventilatory control, and different pathogenetic mechanisms have been postulated accordingly. In our review, we encompass the current knowledge about respiratory abnormalities in PD, as well as the impact of anti-Parkinsonian drugs as either risk or protective factors. A description of putative pathogenetic mechanisms is also provided, and possible treatments are discussed, focusing on the importance of recognising and treating respiratory symptoms as a key manifestation of the disease itself. A brief description of respiratory dysfunctions in atypical Parkinsonism, especially α-synucleinopathies, is also provided.

Identifiers

PMID33043046
PMCPMC7533305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.